1. Home
  2. LCFY vs BOLT Comparison

LCFY vs BOLT Comparison

Compare LCFY & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Locafy Limited

LCFY

Locafy Limited

N/A

Current Price

$1.14

Market Cap

8.3M

Sector

N/A

ML Signal

N/A

Logo Bolt Biotherapeutics Inc.

BOLT

Bolt Biotherapeutics Inc.

N/A

Current Price

$6.35

Market Cap

7.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LCFY
BOLT
Founded
2009
2015
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3M
7.7M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
LCFY
BOLT
Price
$1.14
$6.35
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
★ $41.00
AVG Volume (30 Days)
58.5K
★ 638.1K
Earning Date
11-11-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $7,695,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 0.07
52 Week Low
$1.10
$5.99
52 Week High
$6.20
$14.40

Technical Indicators

Market Signals
Indicator
LCFY
BOLT
Relative Strength Index (RSI) 24.56 61.67
Support Level $1.10 $3.81
Resistance Level $2.75 $7.11
Average True Range (ATR) 0.13 0.56
MACD -0.02 0.28
Stochastic Oscillator 8.34 53.01

Price Performance

Historical Comparison
LCFY
BOLT

About LCFY Locafy Limited

Locafy Ltd is an Australian company currently focused on commercializing its Software as a Service (SaaS) online marketing technology (Technology), which prominently delivers a cost-effective location-based digital marketing solution for small businesses in the key markets of the USA, Australia and Canada. The company has two operating segments: Publishing and SEO Agency. The company derives the majority of its revenue from license subscription fees and advertising fees. Geographically, the maximum revenue is derived from North America.

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.

Share on Social Networks: